國家衛生研究院 NHRI:Item 3990099045/13069

NHRI > National Institute of Infectious Diseases and Vaccinology > Tsai-Ling Yang Lauderdale > Periodical Articles > Item 3990099045/13069

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13069

Title:	Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods
Authors:	Kuo, SC;Tan, MC;Huang, WC;Wu, HC;Chen, FJ;Liao, YC;Wang, HY;Shiau, YR;Lauderdale, TL
Contributors:	National Institute of Infectious Diseases and Vaccinology;Institute of Population Health Sciences
Abstract:	OBJECTIVES: We aimed to determine susceptibilities of Elizabethkingia spp. to 25 commonly tested and 8 novel antibiotics, and to compare the performance of different susceptibility testing methods. METHODS: Clinical isolates of Elizabethkingia spp., Chryseobacterium spp. and Flavobacterium spp. collected during 2002-18 (n = 210) in a nationwide surveillance programme in Taiwan were speciated by 16S rRNA sequencing. MICs were determined by broth microdilution. The broth microdilution results of 18 common antibiotics were compared with those obtained by the VITEK 2 automated system. RESULTS: Among the Elizabethkingia spp. identified (n = 108), Elizabethkingia anophelis was the most prevalent (n = 90), followed by Elizabethkingia meningoseptica (n = 7) and Elizabethkingia miricola cluster [E. miricola (n = 6), Elizabethkingia bruuniana (n = 3) and Elizabethkingia ursingii (n = 2)]. Most isolates were recovered from respiratory or blood specimens from hospitalized, elderly patients. PFGE showed two major and several minor E. anophelis clones. All isolates were resistant to nearly all the tested β-lactams. Doxycycline, minocycline and trimethoprim/sulfamethoxazole inhibited >90% of Elizabethkingia spp. Rifampin inhibited E. meningoseptica (100%) and E. anophelis (81.1%). Fluoroquinolones and tigecycline were active against E. meningoseptica and E. miricola cluster isolates. Novel antibiotics, including imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam, delafloxacin, eravacycline and omadacycline were ineffective but lascufloxacin inhibited half of Elizabethkingia spp. The very major discrepancy rates of VITEK 2 were >1.5% for ciprofloxacin, moxifloxacin and vancomycin. Major discrepancy rates were >3% for amikacin, tigecycline, piperacillin/tazobactam and trimethoprim/sulfamethoxazole. CONCLUSIONS: MDR, absence of standard interpretation criteria and poor intermethod concordance necessitate working guidelines to facilitate future research of emerging Elizabethkingia spp.
Date:	2021-03
Relation:	Journal of Antimicrobial Chemotherapy. 2021 Mar;76(3):653-658.
Link to:	http://dx.doi.org/10.1093/jac/dkaa499
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0305-7453&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000620821900016
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85102152978
Appears in Collections:	[Tsai-Ling Yang Lauderdale] Periodical Articles [Feng-Jui Chen] Periodical Articles [Shu-Chen Kuo] Periodical Articles [Yu-Chieh Liao] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB33258923.pdf		354Kb	Adobe PDF	293	View/Open

Loading...